Dobutamine
Dobutamine is a medicine given into a vein. A US label for dobutamine in 5% dextrose injection lists it, when treatment by injection is needed, for short-term inotropic support, meaning support for a weakly contracting heart, in patients with cardiac decompensation due to depressed contractility. The label names two causes: organic heart disease and cardiac surgical procedures. The label says "Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions." It adds that neither dobutamine nor any other cyclic-AMP-dependent inotrope "has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure." MeSH also notes its use during dobutamine stress echocardiography, a heart test.
Also called Dobutamine hydrochloride
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 3616; UNII 0WR771DJXV is the UNII of the salt, dobutamine hydrochloride, that the label gives, so it is a broad match; MeSH descriptor D004280 (Dobutamine). US drug-label class: beta-Adrenergic Agonist (established pharmacologic class, RxClass). The MeSH scope note describes a catecholamine derivative with specificity for beta-1 adrenergic receptors. The label read is the Baxter Healthcare label for dobutamine hydrochloride in 5% dextrose, application NDA020255, effective 2023-09-08 in openFDA; the vial products under other applications were not read. The indication names cardiac decompensation due to depressed contractility, not heart failure by name. This page records the label indication and the class only: no trial result and no dose is given. The parent class page (inotropes and vasopressors) is not written yet, so the page has no parent link.
Trials at a glance
The figures count the 4 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 4
- Phase 3 or 4
- 3
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Active, not recruiting | Completed | All statuses |
|---|---|---|---|---|
| Phase 2 | 0 | 1 | 0 | 1 |
| Phase 3 | 0 | 0 | 1 | 1 |
| Phase 4 | 1 | 0 | 1 | 2 |
| All phases | 1 | 1 | 2 | 4 |
Conditions these trials study
- Cardiogenic shock
- Acute coronary syndrome
- Cardiomyopathy (heart muscle disease)
- ST-elevation heart attack (STEMI)
Sponsors with the most trials
- Ottawa Heart Institute Research Corporation
- Copenhagen University Hospital, Rigshospitalet
- University Hospital, Limoges
About this drug
- Level
- Substance
- Mechanism
- The label calls dobutamine a direct-acting inotropic agent whose main action comes from stimulating the beta-receptors of the heart.
Classification codes
-
0WR771DJXVDobutamine hydrochloride
Claims and evidence
Context Patients for whom the US dobutamine in dextrose injection label lists inotropic support: cardiac decompensation due to depressed contractility
- Recipient
- Recipient not specified
- Population
- Patients with cardiac decompensation due to depressed contractility from organic heart disease or from cardiac surgical procedures; the indication sentence does not name an age group.
- Care setting
- Intravenous (parenteral) therapy, as the indications section describes
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the indication sentence
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement); the label says controlled-trial experience does not extend beyond 48 hours
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with cardiac decompensation due to depressed contractility from organic heart disease or cardiac surgical procedures
- Excluded
- None stated
The US label of dobutamine hydrochloride in 5% dextrose injection (Baxter Healthcare, NDA020255; version dated 8 September 2023 in openFDA) lists the medicine, when parenteral therapy is necessary, for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility, from organic heart disease or from cardiac surgical procedures. The label says "Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions." It adds that neither dobutamine nor any other cyclic-AMP-dependent inotrope "has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure." It describes the medicine as a direct-acting inotropic agent whose main action is stimulation of the beta-receptors of the heart.
Applies to Recipient not specified Patients for whom the US dobutamine in dextrose injection label lists inotropic support: cardiac decompensation due to depressed contractility
- Certainty method
- Not assessed
- Limitations
- This claim records what one label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded. The indication names cardiac decompensation due to depressed contractility, not heart failure by name. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses and adverse reactions were not recorded. The same active substance is also sold as a vial product under other applications, which were not read. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
- Last checked
- 2026-11-08
- Next evidence check due
- Not scheduled
Sources and citations (8)
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].effective_time
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].openfda.brand_name[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].indications_and_usage[0], 1 sentence 1, fragment 1 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].indications_and_usage[0], 1 sentence 1, fragment 2 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].indications_and_usage[0], 1 sentence 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].indications_and_usage[0], 1 sentence 3, part
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dobutamine Hydrochloride in 5% Dextrose Injection (Baxter, NDA020255)
- Locator
- results[0].clinical_pharmacology[0], 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2023-09-08
- Source state
- Current
- Version fingerprint
ef860ea206236a678237592374a3093a5dbc978ebb897c416743b35200e8719b- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%
No label from the application holder was found in the openFDA label dataset for application NDA020269. This page does not show another labeler's label in its place.
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA020201. This page does not show another labeler's label in its place.
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
No label from the application holder was found in the openFDA label dataset for application NDA020255. This page does not show another labeler's label in its place.
DOBUTREX
No label from the application holder was found in the openFDA label dataset for application NDA017820. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact The US label lists short-term inotropic support in cardiac decompensation due to depressed contractility: Heart failure
Applies to Recipient not specified Patients for whom the US dobutamine in dextrose injection label lists inotropic support: cardiac decompensation due to depressed contractility
The US label of dobutamine hydrochloride in 5% dextrose injection (Baxter Healthcare, NDA020255; version dated 8 September 2023 in openFDA) lists the medicine, when parenteral therapy is necessary, for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility, from organic heart disease or from cardiac surgical procedures. The label says "Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions." It adds that neither dobutamine nor any other cyclic-AMP-dependent inotrope "has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure." It describes the medicine as a direct-acting inotropic agent whose main action is stimulation of the beta-receptors of the heart.Limitations. This claim records what one label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded. The indication names cardiac decompensation due to depressed contractility, not heart failure by name. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses and adverse reactions were not recorded. The same active substance is also sold as a vial product under other applications, which were not read. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 4
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 4
Record details
- Record id
cardio:dobutamine- Content hash
72a2ac856ecd5b9e2ff764852970b12f67dff38d05e861cd42efa75ab1d780b5